|Dr. Allan L. Goldstein Ph.D.||Founder, Chairman, Chief Scientific Officer and Chairman of Scientific Advisory Board||N/A||N/A||79|
|Mr. J. J. Finkelstein||Chief Exec. Officer, Pres and Director||153.36k||N/A||65|
|Mr. Dane R. Saglio||Chief Financial Officer||N/A||N/A||59|
|Mr. Alan Klein MBA||Chief Bus. Officer||N/A||N/A||N/A|
|Mr. Richard J. Hindin||Sec.||N/A||N/A||74|
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue. It also evaluates the commercial development of peptide fragments and derivatives of Tß4 for potential cosmeceutical and other personal care uses. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was founded in 1982 and is headquartered in Rockville, Maryland.
RegeneRx Biopharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.